5,600 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC acquired a new stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,600 shares of the company's stock, valued at approximately $430,000.

Several other hedge funds also recently added to or reduced their stakes in WGS. Gen Wealth Partners Inc acquired a new position in shares of GeneDx in the 4th quarter worth approximately $81,000. Gotham Asset Management LLC raised its position in GeneDx by 23.1% in the fourth quarter. Gotham Asset Management LLC now owns 16,587 shares of the company's stock valued at $1,275,000 after purchasing an additional 3,109 shares during the period. Graham Capital Management L.P. lifted its stake in GeneDx by 38.7% during the fourth quarter. Graham Capital Management L.P. now owns 17,453 shares of the company's stock worth $1,341,000 after purchasing an additional 4,869 shares in the last quarter. Ensign Peak Advisors Inc purchased a new position in shares of GeneDx during the fourth quarter worth $2,068,000. Finally, Farallon Capital Management LLC acquired a new stake in shares of GeneDx in the fourth quarter valued at $14,988,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wells Fargo & Company decreased their target price on GeneDx from $105.00 to $78.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. The Goldman Sachs Group increased their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 19th. Jefferies Financial Group raised shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 target price on the stock in a research note on Friday, May 9th. TD Securities reduced their target price on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Finally, Guggenheim assumed coverage on shares of GeneDx in a research note on Thursday, May 15th. They issued a "buy" rating and a $88.00 price target for the company. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $86.75.

GeneDx Stock Down 0.1%

NASDAQ WGS traded down $0.04 on Thursday, hitting $69.98. 381,141 shares of the stock were exchanged, compared to its average volume of 768,760. GeneDx Holdings Corp. has a fifty-two week low of $19.54 and a fifty-two week high of $117.75. The company has a 50-day moving average price of $82.39 and a 200-day moving average price of $82.17. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The company has a market cap of $2.00 billion, a PE ratio of -35.70 and a beta of 1.96.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported $0.28 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.17. The firm had revenue of $87.12 million during the quarter, compared to the consensus estimate of $79.90 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Keith A. Meister acquired 100,000 shares of the firm's stock in a transaction dated Thursday, May 8th. The stock was acquired at an average cost of $56.01 per share, with a total value of $5,601,000.00. Following the completion of the acquisition, the director now owns 3,008,629 shares of the company's stock, valued at $168,513,310.29. The trade was a 3.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kevin Feeley sold 922 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $94.72, for a total transaction of $87,331.84. Following the transaction, the chief financial officer now directly owns 5,446 shares in the company, valued at $515,845.12. The trade was a 14.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 139,390 shares of company stock valued at $13,043,288. 29.60% of the stock is owned by corporate insiders.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.